There’s a lot of excitement in the field of personalised neoantigen based vaccines and cellular therapies. One of the companies leading the way in this niche is Cambridge, MA based Neon Therapeutics.
At the recent European Society of Medical Oncology Congress (ESMO18) in Munich, one of the much anticipated presentations was the preliminary clinical data for Neon’s personalised neoantigen cancer vaccine (NEO-PV-1).
This was the first data for Neon’s product, as opposed to the work done by Prof Cathy Wu and colleagues that used an academic version of the cancer vaccine (NeoVax).
We heard the initial results for the NT-001 trial that began in November 2016 to explore the combination of nivolumab plus NEO-PV-1 in people with certain metastatic cancers.
In this post, we take a closer look at what the trial told us, why the data failed to impress some, and asked was their commentary fair or should we look at the results differently?
The data was presented by Dr Patrick Ott, who is an Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Melanoma Center and the Center for Immuno-Oncology at the Dana-Farber Cancer Institute in Boston. He kindly spoke to BSB and offered his candid perspectives on the data presented in Munich.